El-Mehairy M M, Shaker A, Ramadan M, Hamza S, Tadros S S
J Int Med Res. 1982;10(2):87-91. doi: 10.1177/030006058201000203.
After 3 weeks of placebo administration, thirty-two mildly or moderately hypertensive patients were treated with hydrochlorothiazide (HCZ) for 3 weeks, then with HCZ plus nadolol, a new beta-adrenergic blocker, for 2 years. The dose of HCZ was 50 mg once daily for all except two patients, who received 50 mg twice a day. The dose of nadolol ranged from 40 mg to 240 mg, once daily. The average supine blood pressure decreased from 182/110 mm Hg at the end of the placebo period to 170/104 mm Hg at the end of treatment with HCZ alone. Nadolol was added to the regimen, and the average supine blood pressure decreased further to 132/88 mm Hg at the end of 3 months of combined therapy. It remained essentially unchanged for the duration of the 2-year study, and no increases in the dosage of either drug were needed. Side-effects were mild, and none required a change in dosage. A once-daily dose of nadolol combined with HCZ appears to be safe and effective therapy for the long-term treatment of mild or moderate essential hypertension.
在服用安慰剂3周后，32名轻度或中度高血压患者接受了3周的氢氯噻嗪（HCZ）治疗，然后接受HCZ加新型β-肾上腺素能阻滞剂纳多洛尔治疗2年。除两名患者每天服用两次50毫克外，所有患者的HCZ剂量均为每日一次50毫克。纳多洛尔的剂量范围为每日一次40毫克至240毫克。安慰剂期结束时平均仰卧血压为182/110毫米汞柱，仅用HCZ治疗结束时降至170/104毫米汞柱。在治疗方案中加入纳多洛尔，联合治疗3个月结束时平均仰卧血压进一步降至132/88毫米汞柱。在为期2年的研究期间，血压基本保持不变，两种药物均无需增加剂量。副作用轻微，无一例需要改变剂量。每日一次剂量的纳多洛尔联合HCZ似乎是长期治疗轻度或中度原发性高血压的安全有效疗法。
